Skip to main content
. Author manuscript; available in PMC: 2015 Sep 2.
Published in final edited form as: Mol Cancer Ther. 2014 Nov 5;14(1):90–100. doi: 10.1158/1535-7163.MCT-14-0496

Figure 4.

Figure 4

LB100 sensitizes SKOV-3 intraperitoneal xenografts to the cytotoxic effects of cisplatin. Mice bearing SKOV-3 intraperitoneal metastatic tumors were treated with PBS (vehicle control) (n=4), LB100 (1.5mg/kg) (n=5), cisplatin (1.5mg/kg) (n=5), or LB100 (1.5mg/kg 1 hr pre-cisplatin) + cisplatin (1.5mg/kg) (n=5) for 6 session given every other day. A, No significant difference in body weight indicates minimal toxicity. B, LB100+cisplatin combination treatment significantly slows tumor growth, as measured by bioluminescence signaling, compared to other treatment groups. Data is represented as mean ± SD of relative total photon flux compared to day 1 of treatment. C, Representative imaging of each treatment group. An average (left) and best (right) responder in the combination group is shown by comparison. D, ex-vivo imaging confirms that the signal obtained originates from tumor cells. E, Western blot obtained from ex-vivo tumor samples illustrates hyperphosphorylation of γH2AX, BRCA-1, Chk-1.